Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3311690 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1CYP3A4LMNATSHR | |
| Tert-Butylamine SCHEMBL27701396 | 0.91 | TDP1 (0.44) | ALDH1A1TDP1CYP3A4LMNATSHR | |
| SCHEMBL826630 | 0.78 | TSHR (0.50) | ALDH1A1TDP1CYP3A4LMNATSHR | |
| SCHEMBL30749767 | 0.78 | HSD17B10 (0.48) | ALDH1A1TDP1CYP3A4LMNATSHR | |
| SCHEMBL30389430 | 0.78 | ALDH1A1 (0.46) | ALDH1A1TDP1CYP3A4LMNATSHR | |
| SCHEMBL3638370 | 0.77 | ALDH1A1 (0.52) | ALDH1A1LMNATSHRROCK1MEN1 | |
| SCHEMBL28720537 | 0.77 | TSHR (0.48) | ALDH1A1TDP1CYP3A4LMNATSHR | |
| SCHEMBL1890124 | 0.76 | ALDH1A1 (0.59) | ALDH1A1CYP3A4LMNAKDM4EMEN1 | |
| SCHEMBL3552198 | 0.76 | ALDH1A1 (0.59) | ALDH1A1CYP3A4LMNAKDM4EMEN1 | |
| SCHEMBL23829919 | 0.75 | ALDH1A1 (0.47) | ALDH1A1TDP1CYP3A4LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103420904-A | Method for preparing 2,4-diaminopyridine | ASCEPION PHARMACEUTICALS INC | 2013-12-04 | — | — | CN | claimed |
| EP-2090571-B1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-16 | — | — | EP | claimed |
| US-7709480-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-04 | — | — | US | claimed |
| EP-1438053-B1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-09-10 | — | — | EP | claimed |
| US-7173028-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-02-06 | — | — | US | claimed |
| US-20060100211-A1 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | claimed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | claimed |
| CN-121537339-A | 4,4' - (Propane-2, 2-diyl) bis (2- ((4-aminopyridine-2-yl) amino) phenol), and synthesis method and application thereof | 山东阳谷华泰化工股份有限公司 | 2026-02-17 | — | — | CN | disclosed |
| CN-121405617-A | 2- ((4-Aminopyridine-2-yl) amino) -4-methylphenol and synthetic method and application thereof | 山东阳谷华泰化工股份有限公司 | 2026-01-27 | — | — | CN | disclosed |
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-25 | — | — | US | disclosed |
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| US-20250011299-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-01-09 | — | — | US | disclosed |
| US-6168843-B1 | LIGHT RESISTANCE; FOR COMPACT DISKS | TDK CORPORATION (JP) | 2001-01-02 | — | — | US | disclosed |
| US-6165998-A | Antifungal agents | SCRIPTGEN PHARMACEUTICALS, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-1008383-A1 | LIPOPROTEIN ADSORBENT AND LIPOPROTEIN ADSORBER MADE WITH THE USE OF THE SAME | KANEKA CORPORATION (JP) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999013714-A1 | ANTIFUNGAL AGENTS | SCRIPTGEN PHARMACEUTICALS, INC. (US) | 1999-03-25 | — | — | WO | disclosed |
| EP-0887202-A1 | OPTICAL RECORDING MEDIUM | TDK Corporation (JP) | 1998-12-30 | — | — | EP | disclosed |
| WO-1995015009-A1 | POROUS CRYSTALLINE MATERIALS HAVING NONLINEAR OPTICAL PROPERTIES | MOBIL OIL CORPORATION (US) | 1995-06-01 | — | — | WO | disclosed |
| US-5348687-A | M41S materials having nonlinear optical properties | MOBIL OIL CORP. (US) | 1994-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100211-A1 | Pyrimidine derivatives | TYMP, TYMS, DPYD | ALDH1A1 252/4885TDP1 166/4885CYP3A4 721/4885 |
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | ALK, TGFBR1, ACVR1 | ALDH1A1 742/4885TDP1 2987/4885CYP3A4 3647/4885 |
| US-20250011299-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, ACVR1 | ALDH1A1 742/4885TDP1 2987/4885CYP3A4 3647/4885 |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | COL1A1, MKI67, INSR | ALDH1A1 605/4885TDP1 795/4885CYP3A4 885/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | ALDH1A1 174/4885TDP1 775/4885CYP3A4 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.